Drug Price Controls in the U.S.: A Roundtable Discussion with Experts

This report attempts to better understand the potential effect of price-setting policies such as H.R.3 on pharmaceutical innovation.

---

10.20.2021

To better understand the potential effect of price-setting policies such as H.R.3 on pharmaceutical innovation, Charles River Associates (CRA) with the support of Incubate, convened a roundtable of diverse industry experts in July 2021. Participants in the discussion included economists, venture capitalists, and representatives of the investor community, current and former pharmaceutical and biotech executives, a former CBO official, and a selection of the academic researchers who authored the studies used by the CBO in their analysis of the H.R.3 impact. The session was conducted according to the Chatham House Rule. Therefore, we summarize the overall discussion from the meeting below without attributing specific comments.